COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT00176332
Previous Study | Return to List | Next Study

Impact of Rosuvastatin on Endothelial Function and Inflammation in Patients With Chronic Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00176332
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : August 1, 2007
Information provided by:
University of Leipzig

Brief Summary:

Statin therapy has been shown to efficiently reduce mortality in patients with coronary artery disease and myocardial infarction, partially as a result of the lipid-lowering properties of statins. However, especially the pleiotropic effects of statins, e.g. their anti-inflammatory and anti-oxidative properties, might be of interest in the treatment of patients with chronic heart failure that are limited in their exercise capacity due to alterations of the skeletal muscle and peripheral endothelial dysfunction.

Aim of this trial is therefore to assess the effects of three months of rosuvastatin treatment on markers of inflammation and oxidative stress in the skeletal muscle and the blood, on postnatal vasculogenesis, and endothelial function of the radial artery in patients with severe chronic heart failure.

Condition or disease Intervention/treatment Phase
Heart Failure Drug: rosuvastatin Phase 2

Detailed Description:

A total of 40 patients with severe chronic heart failure are prospectively randomized to either 3 months of rosuvastatin or placebo treatment.

Before and after the intervention period maximal exercise capacity is measured by ergospirometry and endothelial function is determined by high-resolution A-mode ultrasound. Skeletal muscle biopsies are obtained at begin and after 3 months and are analyzed for inflammatory markers, measures of oxidative stress and vasculogenesis. Blood samples are assessed with regard to markers of inflammation and oxidative stress as well.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Impact of Three Months of Rosuvastatin Treatment on Peripheral Endothelial Function, Inflammatory Markers in the Blood and the Skeletal Muscle and on Postnatal Vasculogenesis in Patients With Severe Chronic Heart Failure
Study Start Date : March 2004
Actual Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Primary Outcome Measures :
  1. Inflammation in the blood and the skeletal muscle
  2. Vasculogenesis
  3. Endothelial function of the radial artery

Secondary Outcome Measures :
  1. Peak oxygen uptake
  2. Left ventricular function

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • chronic heart failure (NYHA class III or IV)
  • peak oxygen uptake <20 mL/min/kg body weight
  • left ventricular ejection fraction <30 %
  • left ventricular end-diastolic diameter >55 mm
  • stable medication within the last 4 weeks

Exclusion Criteria:

  • elevated GOT and GPT levels as a sign of hepatic dysfunction
  • elevated creatinine levels as a sign of renal dysfunction
  • insulin-dependent diabetes mellitus
  • arterial hypertension
  • muscle disease or elevated CK levels
  • treatment with fibrates
  • co-treatment with drugs that are metabolized by Cyp3A4
  • diseases that disallow a participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00176332

Layout table for location information
University of Leipzig, Heart Center, Department of Internal Medicine / Cardiology
Leipzig, Saxony, Germany, 04289
Sponsors and Collaborators
University of Leipzig
Layout table for investigator information
Principal Investigator: Rainer P Hambrecht, MD University of Leipzig, Heart Center, Department of Internal Medicine / Cardiology
Layout table for additonal information Identifier: NCT00176332    
Other Study ID Numbers: 121/2003
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: August 1, 2007
Last Verified: July 2007
Keywords provided by University of Leipzig:
chronic heart failure
endothelial function
skeletal muscle
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors